VolitionRx Limited to Present at the 29th Annual ROTH Conference

NAMUR, Belgium, March 8, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it will present at the 29^th Annual ROTH Conference being held March 12-15, 2017 in Dana Point, CA.

Scott Powell, Executive Vice President of Volition, will provide an update on Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced product launch of its Nu.Q^TM Colorectal Cancer Screening Triage Test.

The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the IR Calendar page of the Investor Relations section of Volition's website at www.volitionrx.com.

Persons attending the conference who would like to schedule a 1-on-1 meeting with Volition management during the conference may do so by contacting Tirth Patel of Edison Advisors at tpatel@edisongroup.com or Scott Powell, Executive Vice President of Volition, at S.Powell@volitionrx.com. 

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics^®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx 
LinkedIn: https://www.linkedin.com/company/volitionrx 
Facebook: https://www.facebook.com/VolitionRx/ 
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Nucleosomics^®, NuQ^®, Nu.Q^TM and HyperGenomics^® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-the-29th-annual-roth-conference-300419997.html

SOURCE VolitionRx Ltd